The lncRNA LINC00691Functions as a ceRNA for miRNA-1256 to Suppress Osteosarcoma by Regulating the Expression of ST5

OncoTargets and Therapy, 2020 · DOI: http://doi.org/10.2147/OTT.S266435 · Published: January 1, 2020

Simple Explanation

Osteosarcoma is a common cancer in children and young adults, often with poor outcomes due to late diagnosis and metastasis. LncRNAs, which are long noncoding RNAs, are being studied for their role in osteosarcoma and as potential treatment targets. This study focuses on LINC00691, an lncRNA, and how it affects osteosarcoma cells. The researchers found that LINC00691 levels are lower in osteosarcoma cells compared to normal cells. By increasing LINC00691 levels, the researchers observed a decrease in the growth, movement, and spread of osteosarcoma cells. They also found that LINC00691 regulates the expression of ST5 by binding to miR-1256.

Study Duration

Not specified

Participants

Osteosarcoma cells (U2OS, Saos-2, MG-63, and HOS), Human osteoblast hFOB1.19 cells, Hff-1 (human foreskin fibroblast-1) and hBMSCs (human bone marrow stem cells), BALB/C nude mice

Evidence Level

Not specified

Key Findings

1
LINC00691 expression is decreased in osteosarcoma cells compared to control cells.
2
Overexpression of LINC00691 inhibits the proliferation, migration, and invasion of osteosarcoma cells in vitro and in vivo.
3
LINC00691 regulates ST5 expression by binding to miR-1256, acting as a ceRNA.

Research Summary

This study investigates the role of lncRNA LINC00691 in osteosarcoma. It demonstrates that LINC00691 expression is downregulated in osteosarcoma cells and tissues. The study reveals that LINC00691 functions as a ceRNA, regulating ST5 expression by binding to miR-1256. This pathway is implicated in the progression and metastasis of osteosarcoma. Overexpression of LINC00691 inhibits EMT by promoting E-cadherin expression and suppressing ZEB1, Snail, and Fibronectin. Xenotransplantation models confirm that LINC00691 overexpression reduces tumor volume.

Practical Implications

Therapeutic Target

The LINC00691/miR-1256/ST5 pathway may represent a novel therapeutic target for osteosarcoma treatment.

Diagnostic Marker

LINC00691 could be used as a potential biomarker for early diagnosis and prognosis evaluation of osteosarcoma.

Treatment Strategies

Understanding the molecular mechanisms of LINC00691 could lead to the development of new therapeutic strategies for osteosarcoma, potentially improving patient outcomes.

Study Limitations

1
The function and mechanism of lncRNAs are diverse.
2
It is difficult to predict the function of lncRNAs only by their sequence.
3
LncRNAs that have not been characterized may encode key proteins or polypeptides, which may affect the functional research of target lncRNAs.

Your Feedback

Was this summary helpful?

Back to Oncology